Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

The major feature of the companion diagnostic testing market is the current domination of tests for mutations important in the prognosis and diagnosis of non-small cell lung cancer (NSCLC), with the two market leaders being Roche and Qiagen. According to Publisher’s forecast, in 2014, NSCLC companion diagnostic tests account for 55% of the market by value.